CLINICAL UPDATES · SEASON 1 · EPISODE 6
Rejection Surveillance: Labs, Biopsies, and What the Numbers Mean
Kidney transplant rejection can develop silently while blood tests still look acceptable. This Clinical Update reviews how surveillance is structured — creatinine trends, donor-specific antibodies, newer blood biomarkers, and biopsy — and what the results actually mean for management.
By Dr. Mohamed Ibrahim, MD, PhD — Assistant Professor of Medicine, Transplant Nephrology, University of Maryland School of Medicine · Last reviewed: November 2026
MedicalVideos Clinical Updates is an educational series produced with full editorial independence. If an episode is sponsor-funded, that funding is labelled on the episode page and on the series hub.
The update
The clinical picture
Rejection comes in two broad mechanisms. T-cell–mediated rejection is an attack by the recipient's lymphocytes on graft tissue, graded by the pattern of inflammation in tubules and vessels. Antibody-mediated rejection is driven by donor-specific antibodies binding graft endothelium, injuring the microcirculation and, over time, producing the chronic scarring patterns that shorten graft life. Both can be clinically silent: creatinine may not move until injury is established. Surveillance exists to catch the process at the signal stage — a drifting creatinine, a new antibody, a rising injury marker — rather than at the damage stage.
The current landscape
Surveillance has expanded beyond creatinine. Donor-specific antibody (DSA) monitoring identifies patients developing an alloimmune response before function falls, and is central to detecting antibody-mediated rejection risk. Donor-derived cell-free DNA (dd-cfDNA) testing adds a graft-injury signal: injured donor tissue releases DNA fragments into the recipient's blood, and elevated levels correlate with active rejection. Gene-expression and urine biomarker panels are used in some centres. None of these replaces biopsy — they triage it, helping teams decide who needs tissue diagnosis now and who can safely continue routine monitoring.
In practice
The routine backbone is scheduled creatinine and drug-level monitoring, frequent in the first months and spacing out over time, with urine protein measurement alongside. Biopsy remains the diagnostic standard, performed for cause — unexplained creatinine rise, new proteinuria, de novo DSA — and as protocol biopsies at set times in some centres and risk groups. Biopsy grading follows the Banff classification, which standardises how rejection type and activity are reported and compared. Every abnormal surveillance result is read against the adherence history and drug levels, because under-immunosuppression is the most common correctable driver.
When to escalate
Escalate for a sustained creatinine rise, new donor-specific antibodies, or a high cell-free DNA result — each triggers a defined pathway rather than watchful waiting. Fever with graft tenderness, falling urine output, or fluid overload suggests acute rejection or infection and needs same-day assessment. When biopsy shows rejection, treatment intensity follows the type and severity, and the follow-up question is always why: under-immunosuppression, nonadherence, or an unusually aggressive immune response each lead to different long-term plans.
Common questions
Does every transplant patient need regular biopsies?
Not usually. Standard blood tests — creatinine and drug levels — are checked first, and many centres add urine protein measurement and donor-specific antibody testing. Biopsy is recommended when results suggest rejection, when kidney function changes without explanation, or as a scheduled protocol biopsy in some programs.
What is donor-derived cell-free DNA?
It is a blood test that measures fragments of DNA from the donor kidney circulating in the recipient's blood. When the graft is injured — by rejection or other causes — more donor DNA is released. A high result prompts closer evaluation; it does not by itself diagnose rejection.
What happens if donor-specific antibodies appear?
That pattern suggests alloimmune activity and triggers action: it may mean doses need review, adherence needs attention, or a biopsy is needed to look for antibody-mediated rejection. New antibodies are taken seriously even when kidney function is still normal.
Can rejection happen with normal blood tests?
Often, yes. Kidney function and blood tests can stay normal while inflammation is already present in the tissue — subclinical rejection. Finding it early is the argument for surveillance biopsies in higher-risk patients, because treatment works better before damage accumulates.
More in Transplant
Related
Related reading
Sources
- Transplant Recipient Guideline (KDIGO)
- Kidney Transplantation (MedlinePlus, US National Library of Medicine)
- Transplant Candidate Guideline (KDIGO)
This Clinical Update is educational content for clinicians and informed patients. It is not medical advice and does not replace the judgment of the treating team. Drug classes are discussed in general terms only; prescribing decisions, doses, and monitoring belong with the patient's own clinicians. Surveillance schedules vary by centre and immunological risk; abnormal results are interpreted by the transplant team.